Vyome (HIND) Stock Price, News & Analysis

Company Overview

ReShape Lifesciences Inc., a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company's product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; and ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach to enable weight loss in obese and morbidly obese patients without cutting or permanently removing portions of the stomach, or bypassing any portion of the gastrointestinal tract. It also offers ReShapeCare virtual health coaching program, a virtual telehealth weight management program that supports healthy lifestyle changes for all medically managed weight-loss patients; and ReShape Diabetes Bloc-Stim Neuromodulation, a technology that is in preclinical development for the treatment of type 2 diabetes mellitus. In addition, the company provides Obalon Balloon System, a swallowable capsule used to track and display the location of the balloon during placement. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in 2017. ReShape Lifesciences Inc. was incorporated in 2002 and is headquartered in San Clemente, California.

Key Stats

• Today's Range: $4.71 to $5.35
• 50-Day Range: N/A
• 52-Week Range: $4.71 to $720.00
• Volume: 83,471 shs
• Average Volume: 888,404 shs
• Market Capitalization: $3.55 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $15.00
• Consensus Rating: Buy

Vyome Stock Analysis - MarketRank™

Vyome scored higher than 55% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.9 / 5
• Analyst Rating: Buy

Consensus Rating

Vyome has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Upside Potential

Vyome has a consensus price target of $15.00, representing about 183.0% upside from its current price of $5.30.

Amount of Analyst Coverage

Vyome has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Vyome is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Vyome is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

5.75% of the float of Vyome has been sold short.

Short Interest Ratio / Days to Cover

Vyome has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Vyome has recently decreased by 4.68%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Vyome does not currently pay a dividend.

Dividend Growth

Vyome does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

5.75% of the float of Vyome has been sold short.

Short Interest Ratio / Days to Cover

Vyome has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Vyome has recently decreased by 4.68%, indicating that investor sentiment is improving.

News and Social Media

• Score: 3.5 / 5
• News Sentiment: 1.27

News Sentiment

Vyome has a news sentiment score of 1.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.42 average news sentiment score of Manufacturing companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Vyome this week, compared to 1 article on an average week.

Search Interest

19 people have searched for HIND on MarketBeat in the last 30 days. This is an increase of 90% compared to the previous 30 days.

MarketBeat Follows

1 people have added Vyome to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Vyome insiders have not sold or bought any company stock.

Percentage Held by Insiders

32.98% of the stock of Vyome is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 22.06% of the stock of Vyome is held by institutions.

HIND Stock Analysis - Frequently Asked Questions

How have HIND shares performed this year?

Vyome's stock was trading at $5.46 at the beginning of the year. Since then, HIND shares have decreased by 2.9% and is now trading at $5.30.

How do I buy shares of Vyome?

Shares of HIND stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Today: 10/14/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Manufacturing
• Industry: Surgical, Medical, And Dental Instruments And Supplies
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:HIND
• CIK: 1427570
• Web: N/A
• Phone: (949) 429-6680
• Fax: N/A
• Employees: 50
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Vyome: $15.00
• High Price Target: $15.00
• Low Price Target: $15.00
• Potential Upside/Downside: +183.0%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($433.08)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$7.13 million
• Net Margins: -69.71%
• Pretax Margin: -69.33%
• Return on Equity: -216.95%
• Return on Assets: -69.42%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.77
• Quick Ratio: 1.97

Sales & Book Value

• Annual Sales: $8.01 million
• Price / Sales: 0.44
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($34.66) per share
• Price / Book: -0.15

Miscellaneous

• Outstanding Shares: 670,000
• Free Float: 451,000
• Market Cap: $3.55 million
• Optionable: N/A
• Beta: 1.05